8-K
filed June 5, 2026, 4:14 PM ET
ticker XERS
CIK 0001867096
other material
confidence high
sentiment neutral
materiality 0.15
Xeris shareholders elect Halkuff and Johnson as directors; approve auditor and say-on-pay
Xeris Biopharma Holdings, Inc.
- Dawn Halkuff elected with 62.6M for, 24.9M withhold; John Johnson with 52.7M for, 34.8M withhold.
- Auditor Ernst & Young ratified for FY2026 with 125.8M for, 1.0M against, 1.4M abstain.
- Advisory say-on-pay approved with 82.2M for, 4.7M against, 0.6M abstain; broker non-votes 40.8M.
- Meeting quorum of 128.3M shares from 172.6M outstanding.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Xeris Biopharma Holdings, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
Each nominee was elected by a plurality vote in accordance with the Company’s Amended and Restated Bylaws, as follows: Class II Director Nominee For Withhold Broker Non-Votes Dawn Halkuff 62,581,577 24,906,166 40,780,330 John Johnson 52,665,077 34,822,666 40,780,330
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Xeris Biopharma Holdings, Inc. shareholders approved Advisory Vote to Approve Named Executive Officer Compensation at the 2026-06-04 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the “Say-on-Pay Vote”). The Company’s stockholders voted as follows to approve such executive compensation for the Company’s named executive officers pursuant to the Say-on-Pay Vote: For Against Abstain Broker Non-Votes 82,230,204 4,658,035 599,504 40,780,330
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
Xeris Biopharma Holdings, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-04
Exact text from the filing
The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstain Broker Non-Votes 125,789,818 1,032,530 1,445,725 —
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.